Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is a promising biotechnology company with a strong pipeline of precision oncology therapies. Their focus on discovering novel drug targets for the treatment of cancer, particularly in the areas of KRAS and PRMT5, makes them a key player in the competitive biotech market. With partnerships and promising data in both pancreatic and lung cancer, the company has the potential for rapid growth and success in the near future. As a result, Tango Therapeutics has a positive outlook, and their stock may be a good investment opportunity.

Bears say

Tango Therapeutics is facing a crowded field in the biotechnology industry, with at least 20 competitors in the KRAS inhibitor space. Additionally, the company may need to access both dilutive and non-dilutive financing options to support operations, which could lead to ownership dilution for investors. Furthermore, there is potential for delayed FDA approval or negative clinical results for their lead asset, TNG462, which could significantly impact the company's financials and stock performance.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.